KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages 63-

  Kim, Ki Hyung ^a,b   Xie, Yanhua ^a   Tytler, Ewan M ^c   Woessner, Richard ^d   Mor, Gil ^a   Alvero, Ayesha B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pusan National University   (South Korea)

^c Kentucky   (United States)

^d ARRAY BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARRY 520; CASPASE; CYTOKINE; DYE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CANCER TISSUE; CELL ISOLATION; CELL SPECIFICITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; SUPERNATANT; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 70350117978     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-63     Document Type: Article

References (34)

1. Schwartz PE: Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res 2002, 107:99-118.
2. Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC Jr: Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1994, 1:181-190.
3. Mutch DG: Surgical management of ovarian cancer. Semin Oncol 2002, 29:3-8.
4. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G: TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006, 66:3859-3868.
5. Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, Leiser A, Schwartz PE, Rutherford T, Mor G: Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene 2008, 27:4712-4723.
6. Vijapurkar U, Wang W, Herbst R: Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer Res 2007, 67:237-245.
7. Woessner R, Corrette C, Allen S, Hans J, Aicher T, Lyssikatos J, Robinson J, Poch G, Hayter L, Cox A, Lee P, Winkler J, Koch K, Wallace E: ARRY-520, a KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumor. 2007 American Association for Cancer Research Annual Meeting; Los Angeles, CA 2007.
8. Bayes M, Rabasseda X, Prous JR: Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2007, 29:625-655.
9. Zhang Y, Xu W: Progress on kinesin spindle protein inhibitors as anti-cancer agents. Anticancer Agents Med Chem 2008, 8:698-704.
10. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF: Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987, 47:414-418.
11. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, Mor G: Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009, 8:158-166.
12. Alvero AB, O'Malley D, Brown D, Kelly G, Garg M, Chen W, Rutherford T, Mor G: Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 2006, 106:599-608.
13. Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, Brown D, Mor G: Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003, 22:2611-2620.
14. Alvero AB, Chen R, Fu H, Montagna M, Schwartz PE, Rutherford T, Silasi D, Steffensen KD, Visintin I, Mor G: Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance. Cell Cycle 2008, 8:158-166.
15. Alvero AB, Montagna MK, Chen R, Kim KH, Kyungjin K, Visintin I, Fu HH, Brown D, Mor G: NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer 2009 in press.
16. Woessner R, Cox A, Koch K, Lee P, Sumeet R, Tunquist B, Walker D, Winkler J: In vivo and pharmacodynamic profiling of the KSP inhibitor ARRY-520 supports potent activity in hematological cancers and drug resistant tumors. Proc Am Assoc Cancer Res 2009, 50:4703.
17. Woessner R, Corrette C, Allen S, Hans J, Aicher T, Lyssikatos J, Robinson J, Poch G, Hayter L, Cox A, Lee P, Winkler J, Koch K, Wallace E: ARRY-520, a KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumors. Proc Am Assoc Cancer Res 2007, 48:1433.
18. Lassus P, Opitz-Araya X, Lazebnik Y: Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002, 297:1352-1354.
19. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES: Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 2002, 277:13430-13437.
20. Wagner KW, Engels IH, Deveraux QL: Caspase-2 can function upstream of bid cleavage in the TRAIL apoptosis pathway. J Biol Chem 2004, 279:35047-35052.
21. Shin S, Lee Y, Kim W, Ko H, Choi H, Kim K: Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. EMBO J 2005, 24:3532-3542.
22. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 1998, 74:49-139.
23. Okano J, Rustgi AK: Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem 2001, 276:19555-19564.
24. Blangy A, Lane HA, d'Herin P, Harper M, Kress M, Nigg EA: Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995, 83:1159-1169.
25. Sakowicz R, Finer JT, Beraud C, Crompton A, Lewis E, Fritsch A, Lee Y, Mak J, Moody R, Turincio R, Chabala JC, Gonzales P, Roth S, Weitman S, Wood KW: Antitumor activity of a kinesin inhibitor. Cancer Res 2004, 64:3276-3280.
26. Tao W, South VJ, Diehl RE, Davide JP, Sepp-Lorenzino L, Fraley ME, Arrington KL, Lobell RB: An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. Mol Cell Biol 2007, 27:689-698.
27. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
28. Rothwarf DM, Karin M: The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999, 1999:RE1.
29. Vainer GW, Pikarsky E, Ben-Neriah Y: Contradictory functions of NF-kappaB in liver physiology and cancer. Cancer Lett 2008, 267:182-188.
30. Greten FR, Karin M: The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 2004, 206:193-199.
31. Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A: The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001, 31:2448-2457.
32. Lazar-Molnar E, Hegyesi H, Toth S, Falus A: Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000, 12:547-554.
33. Nicolini A, Carpi A, Rossi G: Cytokines in breast cancer. Cytokine Growth Factor Rev 2006, 17:325-337.
34. Alvero AB, Aldo P, Mor G: MyD88-positive ovarian cancer cells regulate monocyte migration and differentiation. Annual Meeting of American Society for Reproductive Immunology; Nashville, TN 2006.